Hugo expands procedures and indications
Medtronic's stated procedure momentum and expected U.S. general-surgery and gynecology expansions indicate a widening competitive push in soft-tissue robotics. The company is pairing platform growth with an operating-room technology stack, raising the importance of ecosystem breadth.
By the end of the fiscal year, we expect Hugo to surpass 50,000 completed procedures with procedure growth continuing at more than twice the market rate. We are also advancing our platform through new capabilities and new indications, including the expected U.S. expansions into general surgery and gynecology. We are investing in building out a broader surgical ecosystem, just like in CST. An ecosystem that integrates robotics, advanced visualization, navigation, instrumentation, and digital technologies, including AI-enabled capabilities like Touch Surgery.
Who it touches
- MDTbullish
Hugo procedure growth above the market rate and expected new U.S. indications support Medtronic's robotics ramp.
- ISRGbearish
A faster-growing Hugo platform and planned U.S. indication expansion signal intensifying competitive activity in soft-tissue robotics.
About this signal
- Company
- Medtronic plc
- Category
- competition
- Call
- Q1 FY2027